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(MPO) -463G>A polymorphism in Kawasaki disease (KD) patients, and the relationship between
gene polymorphism and MPO levels.
Methods: A total of 334 KD children and 492 sex-matched controls were assayed for polymor-
phism analysis. TaqMan assays were used for genotyping. MPO was measured in 37 KD patients
and 42 febrile controls.
Results: A significant linear trend of KD risk was found to be related to the G/G genotype (plinear
trendZ 0.032). The combined genotypes (G/A and A/A) of MPO -463G>A were associated with a
significantly decreased KD risk compared to the G/G genotype [adjusted odds ratios
(AOR)Z 0.71, 95% confidence interval (CI): 0.52e0.99, pZ 0.040]. In addition, KD patients withVeterans General Hospital, 386 Ta-Chung 1st Road, 813 Kaohsiung, Taiwan, ROC.
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Myeloperoxidase polymorphisms and Kawasaki disease 789A allele were associated with a significantly decreased KD risk as compared to those with G allele
(AORZ 0.73, 95% CI: 0.54e0.98, pZ 0.033). MPO levels were significantly elevated in KD patients
inpreintravenous immunoglobulin (pre-IVIG) stagecompared to febrilecontrols (pZ0.002). KDpa-
tients in pre-IVIG stage had significantly higher MPO levels than febrile controls in terms of G/G ge-
notype (pZ 0.003) and G allele (p< 0.001). KD patients with A allele had significantly lower MPO
levels than those with G allele in post-IVIG acute stage (pZ 0.042). However, there was no signif-
icant difference of individual MPO change for KD patients from pre- to post-IVIG stage in terms of
genotypes (pZ 0.837) or alleles (pZ 0.631).
Conclusion: Our results suggest that G allele of MPO -463G>A polymorphism is a potential genetic
marker for KD risk in Taiwanese children.
Copyrightª 2015,Taiwan Society ofMicrobiology. Publishedby Elsevier Taiwan LLC.This is anopen
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Kawasaki disease (KD), an acute systemic vasculitis with a
predilection for the Asian race, occurs mainly in infants and
children under 5 years of age. It is frequently complicated
by the development of coronary artery lesions (CALs) and
recognized as the leading cause of acquired heart disease in
children.1 Treatment with a single high dose of intravenous
immunoglobulin (IVIG) is effective in reducing the inci-
dence of CALs.2,3 Its pathogenesis remains unclear.
Oxidative stress is a disturbance in the balance of
reactive oxygen species (ROS) and antioxidants, leading to
damage of lipids, proteins, and nucleic acids. Niwa and
Sohmiya4 found that oxygen intermediates increased during
the early stage of KD. Shen and Wang5 reported a KD infant
with IVIG resistance who showed dramatic responsiveness
to the addition of antioxidants (a-tocopherol and ascorbic
acid). Cheung et al’s6 findings suggest that oxidative stress
is increased in KD patients with coronary aneurysms and is
associated with carotid intima-media thickening and stiff-
ening. Takatsuki et al3 found that KD patients in acute stage
suffered from obvious hyperoxidant stress, which improved
in response to IVIG treatment in most patients. Kaneko
et al7 demonstrated that children with acute KD experi-
enced oxidative stress characterized by increased ROS and
decreased biological antioxidant potential. Straface et al’s8
observations further lead to hypothesize that the simulta-
neous oxidative and nitrative stress may play a pathogenic
role in the coronary arteritis associated with KD. These
studies3e8 suggest that oxidative stress plays an important
role in the pathogenesis of KD in both the acute and chronic
stages.
Myeloperoxidase (MPO), a highly oxidant enzyme, gen-
erates ROS and is a key biomarker of vascular inflamma-
tion.9,10 Elevated MPO levels have been detected in acute
KD patients.8,11 A recent study with MPO-deficient mice did
not show vasculitis by using a murine model of KD.12 These
limited data on humans or animals8,11,12 suggest potential
mechanisms for MPO in the development of KD. Research
into MPO polymorphism has largely focused on a single
nucleotide polymorphism -463G>A (Genbank IDs:
rs2333227).13 G allele binds the SP1 transcription factors
more strongly and is associated with 25-fold higher MPO
levels than A allele.14 Therefore, it is biologically plausiblethat MPO -463G>A polymorphism may modulate the risk of
KD. MPO -463G>A polymorphism is reported to be associ-
ated with susceptibility to several vascular diseases,
including coronary artery disease,15e17, lupus nephritis,18
and MPO-ANCA-associated vasculitis in women.19 There
has been no research on MPO polymorphism and risk of KD.
The purpose of this study was to investigate MPO -463G>A
polymorphism in KD patients. In addition, the relationship
of genotypic and allelic types with MPO levels in KD was also
evaluated.Materials and methods
Patients studied
We performed a study at the Department of Pediatrics,
Kaohsiung Veterans General Hospital (KVGH), Kaohsiung,
Taiwan. Medical records of all children who fulfilled the
diagnostic criteria for KD1 in our hospital between 1990 and
2013 were reviewed. Medical records were reviewed for
age, sex, presenting symptoms, complications, and labo-
ratory data within 7 days of illness. A total of 334 unrelated
Han-Chinese children who met the established criteria of
acute KD and had no evidence of viral or bacterial infection
were enrolled for polymorphism analysis. Patients were
treated with a high dose IVIG (2 g/kg) as a single infusion for
10e12 hours without concomitant aspirin therapy1 at KVGH.
Patients who had defervescence within 48 hours after the
completion of IVIG treatment were categorized as the IVIG-
responsive group, and those whose fever persisted or
recrudesced for at least 48 hours but not longer than 7 days
after completion of IVIG treatment were categorized as the
IVIG-resistant group. A total of 250 patients who received
initial IVIG treatment within 10 days of fever were
recruited for analysis of IVIG resistance, excluding 84 pa-
tients who had missing clinical data (n Z 22), did not
receive IVIG treatment (N Z 55), or received initial IVIG
treatment beyond 10 days of fever (n Z 7). Acute and
chronic CALs are defined, respectively, as CALs within 2
weeks of illness and beyond 1 year. CALs were defined as
follows: (1) internal lumen diameter  3 mm in children
younger than 5 years; (2) internal lumen diameter  4 mm
in children older than 5 years, (3) internal lumen diameter
Table 1 Comparisons of demographic data in KD patients and controls.
Factor/category MPO polymorphism analysis Combined MPO level and polymorphism analysis
KD children
(n Z 334)
Controls
(n Z 492)
p KD children
(n Z 37)
Febrile controls
(n Z 42)
p
n (%) n (%) n (%) n (%)
Age (mo; Mean  SD) 28.4  28.8 615.5  120.8 <0.001a 24.7  26.5 25.2  15.7 0.920a
 12 103 (30.8) 0 (0) <0.001b 12 (32.4) 11 (26.2) 0.533c
12e60 196 (58.7) 0 (0) 24 (64.9) 31 (73.8)
> 60 35 (10.5) 492 (100.0) 1 (2.7) 0 (0.0)
Sex 0.999b 0.957b
Female 131 (39.2) 193 (39.2) 13 (35.1) 15 (35.7)
Male 203 (60.8) 299 (60.8) 24 (64.9) 27 (64.3)
Clinical data
With/without IVIG
resistance/excluded
29/221/84 3/34/0 1.000d
With/without acute
CALs/excluded
125/186/23 20/17/0 0.366e
With/Without chronic
CALs/excluded
33/278/23 2/35/0 1.000f
Values in bold font were statistically significant.
a p value was estimated by ManneWhitney U test.
b p value was estimated by Chi-square test.
c p value was estimated by Fisher’s exact test.
d p value was estimated by Fisher’s exact test after 84 KD children were excluded.
e p value was estimated by Chi-square test after 23 KD children were excluded.
f p value was estimated by Fisher’s exact test after 23 KD children were excluded.
CAL Z coronary artery lesion; KD Z Kawasaki disease; MPO Z myeloperoxidase; SD Z standard deviation.
790 K.-P. Weng et al.1.5 times that of an adjacent segment; or (4) clearly
irregular coronary artery lumen.20 A total of 311 patients
were recruited for analysis of CALs, excluding 23 patients
with missing clinical data. For polymorphism analysis, the
control group comprised 492 sex-matched Han-Chinese
controls without individual histories of KD, and autoim-
mune, allergic, or inflammation-associated diseases. For
the combined MPO level and polymorphism analysis, we
enrolled 37 KD children with similar demographic [age
(p Z 0.239), sex (p Z 0.875)] and clinical data to the 334
KD children (Table 1). Forty-two febrile Han-Chinese con-
trols with a clinically viral syndrome as well as without a
history of KD were recruited and matched to 37 KD cases on
age and sex.
Blood samples were collected for the analysis of MPO
levels and polymorphism. This study was approved by the
Institutional Review Board of KVGH. All written informed
consents were obtained from guardians on the behalf of the
children involved in this study and from all adult control
individuals.Polymorphism genotyping
MPO (-463G>A, rs2333227) was performed by the TaqMan
real-time polymerase chain reaction assay using the ABI
PRISM 7500 Sequence Detection System (Applied Bio-
systems, Factor City, CA, USA) in the 96-well format. Po-
lymerase chain reactions were carried out in a reaction
volume of 10 mL containing 10 ng DNA, 5 mL of 2 TaqMan
Universal PCR Master Mix (Applied Biosystems), 0.5 mL 20
primer/probe mixture, and ddH2O (added to a final volumeof 10 mL). The allelic-specific fluorescence data from each
plate were analyzed using the SDS versin 1.3.1 software
(Applied Biosystems, 2005) to automatically determine the
genotype of each sample.
MPO measurements
MPO level in four different stages was measured in 37 KD
patients. Plasma sample was collected in pre-IVIG acute
(5.1  1.9 days from fever onset), post-IVIG acute
(9.3  2.6 days from fever onset), subacute (36.2  15.8
days from fever onset), and convalescent (186.2  160.4
days from fever onset) stages in these KD patients. MPO
level was also measured in 42 age- and sex-matched febrile
controls with a clinically viral syndrome (4.9  1.8 days
from fever onset). The MPO standards, background, and
samples were measured in random duplicate using human
Cardiovascular Disease Panel 2 Magnetic Bead Kit (cat. #
HCVD2MAG-67K, Luminex, magnetic bead) precisely ac-
cording to the guideline of MILLIPLEX MAP assay.
Statistical analysis
Demographic and clinical data between patients with/
without CALs, those with/without IVIG resistance, and
controls were compared by the Chi-square test, Student t
test, or ManneWhitney U test. For each tested single
nucleotide polymorphism (SNP), departure from Har-
dyeWeinberg equilibrium in adult controls was evaluated
by comparing the observed genotypic frequencies with the
expected ones using a goodness-of-fit Chi-square test.
Myeloperoxidase polymorphisms and Kawasaki disease 791Allelic and genotypic frequencies of MPO were compared
between patients with/without CALs, those with/without
IVIG resistance, and controls using simple and multiple lo-
gistic regression, respectively. In addition, multiple logistic
regression was used to evaluate the association between
allelic types, and genotypes of SNPs in MPO with the risk of
CALs, IVIG resistance, and KD, by adjusting various con-
founders, such as sex, age, etc. The crude odds ratios,
adjusted odds ratios (AORs), and 95% confidence intervals
(CIs) were all estimated using multiple logistic regression
models. Expression levels of MPO were presented as median
(range). The difference in demographic and clinical data
between KD cases and controls were evaluated by the Chi-
square test. Student t test, ManneWhitney U test, and
KruskaleWallis one-way analysis of variance were used to
evaluate the differences of MPO expression levels and
laboratory data between KD patients and controls, or be-
tween patients of various genotypes and allelic types.
Wilcoxon sign rank test was used to evaluate KD patients’
individual differences in MPO expression levels between
pre- and post-IVIG stages. A p value <0.05 was considered
statistically significant. The statistical software package of
SPSS (version 17.0; IBM SPSS Inc., Chicago, IL, USA) and SAS/
Genetics (version 9.1.3; SAS Institute Inc., Cary, North
Carolina, USA) were used for all of the statistical analysis.Results
Baseline patient demographic data are summarized in Table
1. A total of 334 KD patients (M/F 203/131, mean age
28.4  28.8 months) and 492 sex-matched controls (M/F
299/193, mean age 615.5  120.8 months) were assayed for
polymorphism analysis. The proportion of older age (> 60
months) in KD patients was significantly less than that in
controls (p < 0.001). There were significant differences
between two groups in terms of age (p < 0.001). However,
no significant differences were observed between two
groups in terms of sex. There were 28 patients with IVIG
resistance and 212 without IVIG resistance. The remainingTable 2 Distribution and odds ratios for risk of KD by various g
SNP of MPO
(-463G>A)
rs2333227
Genotype or
allelic type
334
KD children Controls CO
n (%) n (%)
G/G 259 (77.5) 350 (71.1) 1.
G/A 71 (21.3) 131 (26.6) 0.
A/A 4 (1.2) 11 (2.2) 0.
p
G/A þ A/A 75 (22.5) 142 (28.8) 0.
G allele 589 (88.2) 831 (84.5) 1.
A allele 79 (11.8) 153 (15.5) 0.
c2 0.09
HW p value 0.759
Values in bold font were statistically significant.
a p value was estimated by logistic regression.
b AOR adjusted for sex; p value was estimated by logistic regression
AOR Z adjusted odds ratio; COR Z crude odds ratio; KD Z Kawa
morphism; MPO Z myeloperoxidase.94 patients who had missing clinical data (n Z 32), did not
receive IVIG treatment (N Z 55), or received initial IVIG
treatment beyond 10 days of fever (n Z 7) were excluded
from the analysis of IVIG resistance. A total of 301 patients
were recruited for the analysis of CALs, excluding 33 pa-
tients with missing clinical data.
A total of 37 KD patients (M/F 24/13, mean age
24.7  26.5 months) and 42 age- and sex-matched febrile
controls (M/F 27/15, mean age 25.2  15.7 months) were
recruited for combined MPO level and polymorphism anal-
ysis (Table 1). Of the 37 KD patients, three patients had IVIG
resistance, 20 acute CALs, and two chronic CALs (Table 1).
Genotypic and allelic frequencies of MPO
polymorphisms in KD patients and controls
The genotypic and allelic frequencies of MPO -463G>A
polymorphisms in KD patients and controls are shown in
Table 2. Genotype distributions of controls (n Z 492) were
in HardyeWeinberg equilibrium (p Z 0.759). Compared to
G/A or A/A genotypes, there was no significant association
between KD risk and the G/G genotype, but a significant
linear trend of KD risk was found to be related to the G/G
genotype (plinear trend Z 0.032). Further analysis revealed
that the combined genotypes (G/A and A/A) of MPO
-463G>A were associated with a significantly decreased KD
risk than the G/G genotype (AOR Z 0.71, 95% CI:
0.52e0.99, p Z 0.040). In addition, patients with A allele
were associated with a 1.37-fold increased protection of KD
as compared to those with G allele (AOR Z 0.73, 95% CI:
0.54e0.98, p Z 0.033).
Age, sex, times of IVIG treatment, laboratory
findings, and genotypic and allelic frequencies of
MPO polymorphisms in KD patients with and
without CALs in acute and chronic stages
A total of 311 patients with and without CALs in acute and
chronic stages were recruited for analysis (data not shown).enotypic and allelic frequencies of MPO.
KD patients versus 492 controls
R (95% CI) pa AOR (95% CI) pb
00 1.00
73 (0.53e1.02) 0.065 0.73 (0.53e1.02) 0.065
49 (0.16e1.56) 0.228 0.49 (0.15e1.56) 0.228
for linear trend 0.032 p for linear trend 0.032
71 (0.52e0.985) 0.040 0.71 (0.52e0.99) 0.040
00 1.00
73 (0.54e0.98) 0.033 0.73 (0.54e0.98) 0.033
.
saki disease; HW= Hardy-Weinberg; SNP=single nucleotide poly-
Figure 1. MPO levels of KD patients in acute stage and
febrile controls. KD patients in pre-IVIG acute stage had
significantly higher MPO levels than febrile controls. MPO levels
in KD patients decreased immediately after IVIG treatment and
did not differ significantly from those in febrile controls.
Central box shows values from lower to upper quartile (25e75
percentile). In the box plots, the middle line represents the
median. An outside value is defined as a value that is smaller
than the lower quartile minus 1.5 times the interquartile
range, or larger than the upper quartile plus 1.5 times the
interquartile range (inner fences). These values are plotted
with a round marker. A far out value is defined as a value that is
smaller than the lower quartile minus three times the inter-
quartile range, or larger than the upper quartile plus three
times the interquartile range (outer fences). These values are
plotted with an asterisk marker. IVIG Z intravenous immuno-
globulin; KD Z Kawasaki disease; MPO Z myeloperoxidase.
792 K.-P. Weng et al.Male patients tended to have a higher risk of the acute CALs
(p Z 0.033). Compared to KD patients without acute CALs,
those with acute CALs received more times of IVIG treat-
ment (p < 0.001). KD patients with chronic CALs received
more times of IVIG treatment than those without chronic
CALs (p Z 0.032). In case of acute CALs, there were sig-
nificant differences between two groups in terms of white
blood cell count (pZ 0.006), neutrophil count (pZ 0.003),
and lymphocyte count (p Z 0.003).
Genotype distributions of KD children without acute
CALs (n Z 186) or without chronic CALs (n Z 273) were in
HardyeWeinberg equilibrium (among those without acute
CALs, p Z 0.916; among those without chronic CALs,
p Z 0.930). After adjusting confounders, no significant
association was found between CALs and MPO -463G>A
polymorphisms (data not shown).
Age, sex, laboratory findings, and genotypic and
allelic frequencies of MPO polymorphisms in KD
patients with and without IVIG resistance
A total of 250 patients who received initial IVIG treatment
within 10 days of fever were recruited for analysis (data not
shown). After chart review, 29 patients (M/F 19/10, mean
age 32.3  31.5 months) were identified as being IVIG
resistant and the remaining 221 patients (M/F 132/89,
mean age 25.8  26.2 months) as being IVIG responsive.
There were significant differences between the two groups
in terms of white blood cell count (p Z 0.036) and hemo-
globin count (p Z 0.008).
Genotype distributions of KD patients without IVIG
resistance were in HardyeWeinberg equilibrium
(pZ 0.783). After adjusting for confounders, no significant
association was found between the risk of IVIG resistance
and MPO -463G>A (data not shown).
Association between MPO level and MPO -463G>A
polymorphisms in KD children and febrile controls
KD patients in pre-IVIG stage had significant higher MPO
levels than febrile controls [254.0 (44e1459) ng/mL vs.
138.0 (53e547) ng/mL, p Z 0.002, Figure 1]. MPO levels in
KD patients decreased immediately after IVIG treatment
[254.0 (44e1459) ng/mL vs. 131.0 (31e388) ng/mL,
p < 0.001, Figure 1]. MPO levels in post-IVIG stage did not
differ significantly from those in febrile controls [131.0
(31e388) ng/mL vs. 138.0 (53e547) ng/mL, p Z 0.420,
Figure 1]. MPO levels were further compared between pre-
IVIG KD patients and febrile controls in terms of G/G and G/
AþA/A genotypes. These levels in pre-IVIG KD patients
were significantly higher than those in febrile controls in
terms of G/G genotype (p Z 0.003), but the above
expression differences were not observed between two
groups in terms of G/AþA/A genotypes (p Z 0.448;
Figure 2). Similarly, MPO levels of pre-IVIG KD patients and
febrile controls were compared in terms of G and A alleles.
These levels in pre-IVIG KD patients were significantly
higher than those in febrile controls in terms of G allele
(p < 0.001), but the above expression differences were not
observed between two groups in terms of A allele
(p Z 0.275, Figure 2). Compared to febrile controls,upregulation of MPO levels was found to be correlated with
G/G genotype (p Z 0.003) and G allele (p < 0.001) in pre-
IVIG KD patients.Association of MPO levels with MPO -463G>A
polymorphisms in KD children at various stages
Patients with GA or AA genotype had lower MPO levels than
those with GG genotype in post-IVIG acute stage, but there
was no statistical significance (pZ 0.099, Table 3). Patients
with A allele had significantly lower MPO levels than those
with G allele in post-IVIG acute stage (pZ 0.042, Table 3).
However, there was no significant difference of individual
Figure 2. Expression of MPO in pre-IVIG KD patients and febrile controls according to the SNP of MPO (-463G>A) rs2333227. (A)
Expression of MPO in pre-IVIG KD patients and febrile controls according to genotype of MPO (-463G>A). (B) Expression of MPO in
pre-IVIG KD patients and febrile controls according to allelic type of MPO (-463G>A). IVIG Z intravenous immunoglobulin;
KD Z Kawasaki disease; MPO Z myeloperoxidase; SNP=single nucleotide polymorphism.
Myeloperoxidase polymorphisms and Kawasaki disease 793MPO change for KD patients from pre- to post-IVIG stage in
terms of genotypes (p Z 0.837) or alleles (p Z 0.631).
Association of neutrophil number and MPO level
with IVIG resistance, acute CALs, and chronic CALS
in KD patients at various stages
There was no significant association of neutrophil number
with IVIG resistance and chronic CALs at the four different
stages (all p > 0.05; Table 4). There was a significant associ-
ation between neutrophil number and acute CALS in pre-IVIGTable 3 Comparisons of MPO level for KD patients by MPO -463
Stage MPO -463G>A
GG GAþAA
n (%) n (%)
31 (83.8) 6 (16.2)
Median (range) Median (range)
Pre-IVIG 265.0 (74e1459) 220.8 (44e623)
Post-IVIG 137.0 (31e388) 72.0 (51e239)
Subacute 89.0 (28e223) 67.5 (34e208)
Convalescent 58.5 (26e217) 63.5 (44e185)
Post-IVIGepre-I
VIGa
116.0 (1278 to 101) 151.8 (384 to 7)
Values in bold font were statistically significant.
a Change in individual MPO levels between post-IVIG and pre-IVIG s
b p value was estimated by ManneWhitney U test.
IVIG Z intravenous immunoglobulin; KD Z Kawasaki disease; MPO Zstage (p Z 0.006), but no significant association between
neutrophil number and acute CALS in the other three stages
(all p> 0.05; Table 4). There was no significant association of
MPO levels with IVIG resistance, acute CALs, and chronic CALs
at the four different stages (all p > 0.05; Table 4).
Discussion
Our study showed that there was a significant association
between MPO -463G>A polymorphism and susceptibility of
KD in Taiwanese KD children. To the best of our knowledge,G>A genotypes and alleles at various stages.
MPO -463G>A
pb G allele A allele pb
n (%) n (%)
67 (90.5) 7 (9.5)
Median (range) Median (range)
0.484 265.0 (44e1459) 254.0 (44e623) 0.518
0.099 137.0 (31e388) 63.0 (51e239) 0.042
0.434 89.0 (28e223) 59.0 (34e208) 0.196
0.578 58.5 (26e217) 74.0 (44e185) 0.276
0.837 116.0 (1278e101) 197.0 (384e7) 0.631
tages.
myeloperoxidase.
Table 4 Comparisons of neutrophil number and MPO level of 37 KD patients by at various stages.
Factor/category Pre-IVIG Post-IVIG Subacute Convalescent
n (%) Median (range) pa n (%) Median (range) pa n (%) Median (range) pa n (%) Median (range) pa
Neutrophil number (103/mm3)
IVIG resistance
No 34 (91.9) 5.8 (0.4e17.1) 0.373 34 (91.9) 2.7 (0.5e11.9) 0.541 26 (89.7) 2.3 (0.2e7.4) 0.474 15 (83.3) 2.0 (0.7e8.3) 0.953
Yes 3 (8.1) 4.8 (3.6e7.3) 3 (8.1) 4.3 (1.8e9.1) 3 (10.3) 3.2 (1.9e4.1) 3 (16.7) 2.0 (1.1e3.0)
Acute CALs
No 17 (45.9) 4.8 (0.4e12.9) 0.006 17 (45.9) 2.6 (0.6e11.9) 0.670 12 (41.4) 1.7 (0.2e7.4) 0.063 7 (38.9) 2.1 (1.3e3.2) 0.821
Yes 20 (54.1) 8.7 (3.6e17.1) 20 (54.1) 2.9 (0.5e9.6) 17 (58.6) 2.7 (1.0e4.9) 11 (61.1) 2.0 (0.7e8.3)
Chronic CALs
No 35 (94.6) 5.7 (0.4e17.1) 0.946 35 (94.6) 2.7 (0.5e11.9) 0.788 27 (93.1) 2.3 (0.2e7.4) 0.931 16 (88.9) 2.0 (0.7e8.3) 0.399
Yes 2 (5.4) 6.1 (4.8e7.3) 2 (5.4) 5.5 (1.8e9.1) 2 (6.9) 2.5 (1.9e3.2) 2 (11.1) 1.6 (1.1e2.1)
MPO level
IVIG resistance
No 34 (91.9) 254 (44e1459) 0.978 34 (91.9) 129 (31e388) 0.540 34 (91.9) 83.5 (28e233) 0.436 34 (91.9) 63.3 (26e217) 0.330
Yes 3 (8.1) 289 (92e509) 3 (8.1) 223 (63e263) 3 (8.1) 88 (76e220) 3 (8.1) 45 (44e72)
Acute CALs
No 17 (45.9) 221 (79e1459) 0.464 17 (45.9) 107 (31e359) 0.190 17 (45.9) 95 (30e223) 0.796 17 (45.9) 58 (26e217) 0.927
Yes 20 (54.1) 300 (44e1299) 20 (54.1) 151.5 (50e388) 20 (54.1) 83 (28e220) 20 (54.1) 63.3 (26e185)
Chronic CALs
No 35 (94.6) 254 (44e1459) 0.523 35 (94.6) 131 (31e388) 0.840 35 (94.6) 89 (28e223) 0.840 35 (94.6) 58.5 (26e217) 0.687
Yes 2 (5.4) 190.5 (92e289) 2 (5.4) 143 (63e223) 2 (5.4) 82 (76e88) 2 (5.4) 58.5 (45e72)
Values in bold font were statistically significant.
a p value was estimated by ManneWhitney U test.
CAL Z coronary artery lesion; IVIG Z intravenous immunoglobulin; KD Z Kawasaki disease; MPO Z myeloperoxidase.
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Myeloperoxidase polymorphisms and Kawasaki disease 795this was the first study to investigate the association be-
tween KD risk and MPO polymorphisms. Genotypic and
allelic frequencies did not, however, differ between pa-
tients with and without CALs. There was also no significant
association between the risk of IVIG resistance and MPO
-463G>A. Compared to febrile controls, KD patients had
significantly higher MPO levels in the pre-IVIG acute phase.
In addition, patients with A allele had significantly lower
MPO levels than those with G allele in the post-IVIG acute
phase.
There are growing data on the involvement of oxidative
stress in the overproduction of ROS in KD.3,4,6e8 However,
whether ROS is a cause or consequence of KD is still an
unsolved issue. Furthermore, ROS are composed of abun-
dant molecules, so their specificity as a signaling molecule
has been questioned in a previous report.21 These cross-
sectional studies3,4,6e8 need to be re-evaluated with other
biomarkers for exploring the effects of oxidative stress on
subsequent development of KD. MPO can generate an array
of diffusible oxidants and contribute to oxidative stress.22 It
is abundant in granules of human inflammatory cells such as
activated neutrophils, etc.22 Neutrophil activation has been
suggested to play an important role in KD pathogenesis.23,24
In this series, the significant association between neutro-
phil number and acute CALs in KD patients provides partial
evidence of the involvement of neutrophils in the patho-
genesis of KD. The effect of MPO in vasculitis might be
related to direct production of ROS, facilitation of neutro-
phil priming or activation, elevation of extracellular pro-
teolytic activity, or contribution to endothelial
dysfunction.25 Therefore, MPO may be a potential key
biomarker involved in the development of KD. Rider et al11
reported that MPO levels in acute KD patients (n Z 14)
were significantly higher than those in adult normal con-
trols. Straface et al8 demonstrated that there was an in-
crease in MPO level in acute KD (n Z 8). As the basis for
clinical studies, Su et al’s12 results further showed that MPO
is important in the development of KD and can be a key
functional imaging biomarker for assessing vasculitis in a
murine model of KD. In this series, KD patients had signifi-
cantly higher MPO levels than febrile controls. These find-
ings including ours suggest that MPO may play an important
role in the inflammation induced by KD. Our study further
demonstrated that there was a significant association be-
tween MPO -463G>A polymorphism and susceptibility of
KD. The effect of MPO on KD might be explained by the MPO
-463G>A gene polymorphism in this series.
We observed a significant association between MPO
-463G>A polymorphism and susceptibility of KD in this se-
ries. The combined genotypes (G/A and A/A) of MPO
-463G>A were associated with a significantly decreased KD
risk than the G/G genotype. In addition, KD patients with A
allele were associated with a significantly decreased KD risk
as compared to those with G allele. Increasing evidence
suggests that G allele in MPO polymorphism may determine
the MPO level and play a crucial role in inflammation.14,26e28
Our results showed that KD patients in the pre-IVIG stage had
significantly higher MPO levels than febrile controls in terms
of GG genotype and G allele. This may partially explain the
increased risk of KD associated with the presence of the G
allele observed in the present study. Our results were
compatible with the association of G allele withsusceptibility to disease, such as coronary artery dis-
ease,15,16 MPO-ANCA-associated vasculitis in women,19
acute promyelocytic leukemia,26 diabetic nephropathy,27
lung cancer,29 and digestive tract cancer.30 There is a wide
variation in the A allele frequency of the MPO -463G>A
polymorphism across different ethnicities. The A allele fre-
quency was 22.8% in European population, but approxi-
mately 14.7% in Asian population.31 Compatible with a
previous study conducted in Asian population,31 our results
showed that A allele frequency was 11.8% in KD patients and
15.5% in normal controls. Whether the different MPO A allele
frequencies between Asian and Western countries influence
the incidence of KD is an interesting issue. A replication study
performed in Caucasian countries may further elucidate the
role of MPO polymorphism in KD.
In this series, KD patients with A allele had significantly
lower MPO levels than those with G allele in the post-IVIG
acute phase, implicating a possible allele-modulating effect
on the efficiency of IVIG treatment. Kaneko et al7 reported
that the mechanism of IVIG treatment in KD is associated
with scavenging ROS. The mechanism of IVIG in reducing
inflammation caused by KD is not clearly understood. Mod-
ulation of the production of cytokines, especially tumor
necrosis factor alpha and interleukin 1, is an important
mechanism.32 Tumor necrosis factor alpha can activate
nicotinamide adenine dinucleotide phosphate (NADPH) oxi-
dases in a wide variety of cells and lead to generation of
ROS.33 Two previous studies have also suggested that IVIG
may have antioxidative effects.3,34 These reports3,7,34 may
provide some evidence for themechanism of IVIG in reducing
oxidative stress. However, there was no significant differ-
ence of individual MPO change for KD patients from pre- to
post-IVIG stage in terms of genotypes or alleles. MPO level
was also not associatedwith IVIG resistance. The antioxidant
efficiency of IVIG might not be related to MPO polymorphism
and level. Further studies are required to elucidate the role
of MPO polymorphism in IVIG resistance.
Several aspects of the present study warrant attention.
First, there is no direct evidence to prove that the MPO
level could play an important role in KD. MPO was not
measured in all participants. ROS and neutrophil activation
were also not evaluated. Measurements of various
biomarkers involved in oxidative stress are required to
elucidate the role of MPO in KD. Second, this study was a
single-center investigation of KD patients with modest
sample sizes. Therefore, replication studies with indepen-
dent large cohorts are suggested.
In conclusion, our results suggest that G allele of MPO
-463G>A polymorphism is a potential genetic marker for KD
risk in Taiwanese children.Conflict of interest
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